- Home
- MCBS vs SPRY Comparison
MCBS vs SPRY Comparison
Compare MCBS & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCBS | SPRY |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 816.1M | 761.6M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MCBS | SPRY |
|---|---|---|
| Price | $28.23 | $8.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $32.00 | ★ $40.00 |
| AVG Volume (30 Days) | 92.4K | ★ 1.3M |
| Earning Date | 04-17-2026 | 03-09-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 4.76 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $36.78 | $90.76 |
| Revenue Next Year | $4.83 | $81.70 |
| P/E Ratio | $10.79 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.24 | $6.66 |
| 52 Week High | $31.00 | $18.63 |
Technical Indicators
Market Signals| Indicator | MCBS | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 41.76 |
| Support Level | $26.87 | $6.66 |
| Resistance Level | $29.08 | $10.44 |
| Average True Range (ATR) | 0.70 | 0.59 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 46.61 | 36.68 |
Price Performance
Historical ComparisonAbout MCBS MetroCity Bankshares Inc.
MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.